306 related articles for article (PubMed ID: 30789866)
21. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
22. Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial.
Armstrong AC; Clay V
Future Oncol; 2019 Jul; 15(20):2327-2335. PubMed ID: 31304797
[TBL] [Abstract][Full Text] [Related]
23. The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.
Drew Y; Plummer R
Curr Opin Obstet Gynecol; 2010 Feb; 22(1):67-71. PubMed ID: 19934756
[TBL] [Abstract][Full Text] [Related]
24. Integrating PARP inhibitors into the management of breast cancer: where are we?
Azim HA; Kassem L; Azim H
Chin Clin Oncol; 2021 Jan; 10(5):50. PubMed ID: 33440946
[TBL] [Abstract][Full Text] [Related]
25. [PARP inhibitors in breast cancer: Current clinical development and perspectives].
Robbe J; Moretta J; Vicier C; Sabatier R; Noguès C; Gonçalves A
Bull Cancer; 2020 Oct; 107(10):1024-1041. PubMed ID: 33004179
[TBL] [Abstract][Full Text] [Related]
26. PARP Inhibitors for Breast Cancer Treatment: A Review.
Morganti S; Marra A; De Angelis C; Toss A; Licata L; Giugliano F; Taurelli Salimbeni B; Berton Giachetti PPM; Esposito A; Giordano A; Bianchini G; Garber JE; Curigliano G; Lynce F; Criscitiello C
JAMA Oncol; 2024 May; 10(5):658-670. PubMed ID: 38512229
[TBL] [Abstract][Full Text] [Related]
27. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors.
De Soto JA; Wang X; Tominaga Y; Wang RH; Cao L; Qiao W; Li C; Xu X; Skoumbourdis AP; Prindiville SA; Thomas CJ; Deng CX
Int J Biol Sci; 2006; 2(4):179-85. PubMed ID: 16810332
[TBL] [Abstract][Full Text] [Related]
28. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
Litton JK; Hurvitz SA; Mina LA; Rugo HS; Lee KH; Gonçalves A; Diab S; Woodward N; Goodwin A; Yerushalmi R; Roché H; Im YH; Eiermann W; Quek RGW; Usari T; Lanzalone S; Czibere A; Blum JL; Martin M; Ettl J
Ann Oncol; 2020 Nov; 31(11):1526-1535. PubMed ID: 32828825
[TBL] [Abstract][Full Text] [Related]
29. Talazoparib to treat BRCA-positive breast cancer.
Guney Eskiler G
Drugs Today (Barc); 2019 Jul; 55(7):459-467. PubMed ID: 31347614
[TBL] [Abstract][Full Text] [Related]
30. Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer.
Anampa J; Chen A; Wright J; Patel M; Pellegrino C; Fehn K; Sparano JA; Andreopoulou E
Clin Breast Cancer; 2018 Feb; 18(1):e135-e142. PubMed ID: 28935542
[TBL] [Abstract][Full Text] [Related]
31. Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy.
von Minckwitz G; Müller BM; Loibl S; Budczies J; Hanusch C; Darb-Esfahani S; Hilfrich J; Weiss E; Huober J; Blohmer JU; du Bois A; Zahm DM; Khandan F; Hoffmann G; Gerber B; Eidtmann H; Fend F; Dietel M; Mehta K; Denkert C
J Clin Oncol; 2011 Jun; 29(16):2150-7. PubMed ID: 21519019
[TBL] [Abstract][Full Text] [Related]
32. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
Liu JF; Matulonis UA
Curr Oncol Rep; 2016 May; 18(5):29. PubMed ID: 26984416
[TBL] [Abstract][Full Text] [Related]
33. Development of the PARP inhibitor talazoparib for the treatment of advanced
Hobbs EA; Litton JK; Yap TA
Expert Opin Pharmacother; 2021 Oct; 22(14):1825-1837. PubMed ID: 34309473
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline
Litton JK; Scoggins ME; Hess KR; Adrada BE; Murthy RK; Damodaran S; DeSnyder SM; Brewster AM; Barcenas CH; Valero V; Whitman GJ; Schwartz-Gomez J; Mittendorf EA; Thompson AM; Helgason T; Ibrahim N; Piwnica-Worms H; Moulder SL; Arun BK
J Clin Oncol; 2020 Feb; 38(5):388-394. PubMed ID: 31461380
[TBL] [Abstract][Full Text] [Related]
35. Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results.
Goncalves A; Mezni E; Bertucci F
Curr Opin Oncol; 2020 Nov; 32(6):585-593. PubMed ID: 32852311
[TBL] [Abstract][Full Text] [Related]
36. Moving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer.
Palleschi M; Tedaldi G; Sirico M; Virga A; Ulivi P; De Giorgi U
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360649
[TBL] [Abstract][Full Text] [Related]
37. Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives.
Barchiesi G; Roberto M; Verrico M; Vici P; Tomao S; Tomao F
Front Oncol; 2021; 11():769280. PubMed ID: 34900718
[TBL] [Abstract][Full Text] [Related]
38. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.
Isakoff SJ; Puhalla S; Domchek SM; Friedlander M; Kaufman B; Robson M; Telli ML; Diéras V; Han HS; Garber JE; Johnson EF; Maag D; Qin Q; Giranda VL; Shepherd SP
Future Oncol; 2017 Feb; 13(4):307-320. PubMed ID: 27739325
[TBL] [Abstract][Full Text] [Related]
39.
Lee A; Moon BI; Kim TH
Ann Lab Med; 2020 Mar; 40(2):114-121. PubMed ID: 31650727
[TBL] [Abstract][Full Text] [Related]
40. Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.
Rodler ET; Kurland BF; Griffin M; Gralow JR; Porter P; Yeh RF; Gadi VK; Guenthoer J; Beumer JH; Korde L; Strychor S; Kiesel BF; Linden HM; Thompson JA; Swisher E; Chai X; Shepherd S; Giranda V; Specht JM
Clin Cancer Res; 2016 Jun; 22(12):2855-64. PubMed ID: 26801247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]